Cannabidiol Versus Placebo As Adjunctive Treatment in Early Psychosis: Study Protocol for Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2023 Dec 1

PMID 38037108

Authors

T Dixon

K S Cadenhead

Affiliations

Soon will be listed here.

Abstract

Background: Psychotic disorders are a leading cause of disability in young adults. Antipsychotics have been the primary intervention for psychosis for over 60 years, and yet, we have made little progress in treating negative symptoms, neurocognition, and functional disability. There is growing evidence that cannabidiol (CBD) is effective in treating positive psychotic symptoms, possibly also negative and neurocognitive symptoms, and moreover is well tolerated compared to other psychotropic medications. Anecdotally, patients participating in the Cognitive Assessment and Risk Evaluation (CARE) Early Psychosis Treatment Program at the University of California, San Diego, are self-administering CBD and report subjective improvement in stress, anxiety, and ability to cope with symptoms. The overarching aim of the trial is to explore the effectiveness of CBD augmentation on symptoms and neurocognition in early psychosis while also exploring the mechanism of action of CBD and predictors of response to treatment. The mechanism by which cannabidiol has a therapeutic effect on psychosis is poorly understood. Recent evidence has suggested that CBD may reduce stress and pro-inflammatory biomarker levels. Endocannabinoids also have powerful roles in eating behavior, reward, and mood, indicating these neurotransmitters may play a role in reducing hyperphagia and metabolic abnormalities that are present early in the course of psychotic illness and exacerbated by antipsychotic medication. The neurophysiological effects of CBD have been studied in animal models of psychosis that show improvements in information processing in response to CBD, but there are no studies in individuals with early psychosis.

Method: A total of 120 individuals in the early stages of psychosis will be randomized to 1000 mg of CBD versus placebo as an adjunct to existing treatment in a 8-week, double-blind superiority randomized control trial. The primary outcome measures are symptoms and neurocognition.

Discussion: We hypothesized that CBD will improve symptoms and neurocognition as well as secondary outcome measures of neurohormones, inflammation, eating behaviors, and information processing. Importantly, predictors, moderators, and mediators of the CBD effects will be examined. A better understanding of which individuals are likely to respond to CBD can inform treatment planning and personalize treatment.

Trial Registration: ClinicalTrials.gov NCT04411225. Registered on June 2, 2020.

Citing Articles

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.

Qian L, Beers J, Jackson K, Zhou Z Pharmaceutics. 2024; 16(4).

PMID: 38675145 PMC: 11054161. DOI: 10.3390/pharmaceutics16040484.

References

Muller M, Schlosser R, WETZEL H, Addington D, Benkert O . The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). J Psychiatr Res. 1999; 33(5):433-43. DOI: 10.1016/s0022-3956(99)00018-7. View

First M . Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis. 2013; 201(9):727-9. DOI: 10.1097/NMD.0b013e3182a2168a. View

Keefe R, Harvey P, Goldberg T, Gold J, Walker T, Kennel C . Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008; 102(1-3):108-15. DOI: 10.1016/j.schres.2008.03.024. View

Bergamaschi M, Queiroz R, Chagas M, de Oliveira D, De Martinis B, Kapczinski F . Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011; 36(6):1219-26. PMC: 3079847. DOI: 10.1038/npp.2011.6. View

Koethe D, Hoyer C, Leweke F . The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl). 2009; 206(4):551-61. DOI: 10.1007/s00213-009-1591-7. View

Mackie K . Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008; 20 Suppl 1:10-4. DOI: 10.1111/j.1365-2826.2008.01671.x. View

Mori M, Meyer E, Soares L, Milani H, Guimaraes F, de Oliveira R . Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 75:94-105. DOI: 10.1016/j.pnpbp.2016.11.005. View

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

Izzo A, Borrelli F, Capasso R, Di Marzo V, Mechoulam R . Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30(10):515-27. DOI: 10.1016/j.tips.2009.07.006. View

10.

Bhattacharyya S, Wilson R, Appiah-Kusi E, ONeill A, Brammer M, Perez J . Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. JAMA Psychiatry. 2018; 75(11):1107-1117. PMC: 6248101. DOI: 10.1001/jamapsychiatry.2018.2309. View

11.

Zuardi A, Crippa J, Hallak J, Pinto J, Chagas M, Rodrigues G . Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2008; 23(8):979-83. DOI: 10.1177/0269881108096519. View

12.

Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319-28. DOI: 10.1016/S0140-6736(07)61162-3. View

13.

Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen H, Hansen S . Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol. 2008; 18(11):826-34. PMC: 2745315. DOI: 10.1016/j.euroneuro.2008.06.009. View

14.

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt T . Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002; 325(7374):1212-3. PMC: 135493. DOI: 10.1136/bmj.325.7374.1212. View

15.

Devinsky O, Patel A, Thiele E, Wong M, Appleton R, Harden C . Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018; 90(14):e1204-e1211. PMC: 5890607. DOI: 10.1212/WNL.0000000000005254. View

16.

Gladsjo J, Schuman C, Evans J, Peavy G, Miller S, Heaton R . Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 1999; 6(2):147-78. DOI: 10.1177/107319119900600204. View

17.

Andreasson S, Allebeck P, Engstrom A, Rydberg U . Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987; 2(8574):1483-6. DOI: 10.1016/s0140-6736(87)92620-1. View

18.

Harvey P, Green M, Keefe R, Velligan D . Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004; 65(3):361-72. View

19.

Cadenhead K, Minichino A, Kelsven S, Addington J, Bearden C, Cannon T . Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. Schizophr Res. 2018; 204:96-103. PMC: 6402991. DOI: 10.1016/j.schres.2018.09.022. View

20.

Light G, Braff D . Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005; 62(2):127-36. DOI: 10.1001/archpsyc.62.2.127. View